retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Tirzepatide vs. Retatrutide: Key Differences
Description
Dose adjustment for maintenance: After reaching goal weight, some users reduce from 10-12mg to 6-8mg weekly while maintaining results
doi: 10.2337/dc18-1094
Tirzepatide is a GIP and GLP-1 receptor antagonist that should be approved for weight loss this year by the FDA
Additionally, brands are starting to take notice of shifting dining habits among GLP-1 users
